Pfizer, Inc. (PFE) reported strong earnings and earnings guidance on Feb. 3. Large, unusual call option activity today, as ...

Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical studies in weight management. The company also reported promising pivotal ...

Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of ...

Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Dr. Albert Bourla, Chairman and CEO of Pfizer: “We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Second-quarter 2024 Cost of Sales(4) as a percentage of revenues was relatively flat compared with the prior-year quarter, and reflects favorable changes in sales mix, primarily driven by lower sales ...

WASHINGTON, D.C. -- A major drug company is defending itself against accusations it kept promising and possibly life-saving data secret. The Washington Post reports that Pfizer decided against sharing ...